Biomea Fusion (BMEA) investor relations material

Introduction and agenda

• Discussion focused on the mechanism of action and clinical development of icovamenib, a menin inhibitor for diabetes, and its differentiation from other therapies.

• Agenda included scientific rationale, preclinical and clinical data, patient selection, and future outlook.

Background and experience of the speaker

• Management team has a track record of value creation and novel drug development, particularly in oncology and now diabetes.

Current industry trends

• Menin inhibitors have been successful in oncology, but their application in diabetes is novel.

• GLP-1 receptor agonists are widely used but do not shift the long-term diabetes progression curve.

• There is a growing need for therapies that address beta cell depletion rather than just symptom management.